APA (7th ed.) Citation

Buse, D. C., Lipton, R. B., Urman, R., Vaidya, S. J., Robinson, S. C., Jacobson, A. S., . . . Pressman, A. R. (2026). Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study. Neurology & Therapy, 15(1), 401. https://doi.org/10.1007/s40120-025-00872-1

Chicago Style (17th ed.) Citation

Buse, Dawn C., Richard B. Lipton, Robert Urman, Shruti J. Vaidya, Sarah C. Robinson, Alice S. Jacobson, Alexandra B. Scott, Mark E. Bensink, and Alice R. Pressman. "Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study." Neurology & Therapy 15, no. 1 (2026): 401. https://doi.org/10.1007/s40120-025-00872-1.

MLA (9th ed.) Citation

Buse, Dawn C., et al. "Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study." Neurology & Therapy, vol. 15, no. 1, 2026, p. 401, https://doi.org/10.1007/s40120-025-00872-1.